Javier A. Menéndez
About
Javier A. Menéndez is a scholar working on Molecular Biology, Cancer Research and Oncology.
According to data from OpenAlex, Javier A. Menéndez has authored 314 papers receiving a total of 16.6k indexed citations (citations by other indexed papers that have themselves been cited), including 182 papers in Molecular Biology, 104 papers in Cancer Research and 91 papers in Oncology. Recurrent topics in Javier A. Menéndez's work include Cancer, Lipids, and Metabolism (69 papers), Metabolism, Diabetes, and Cancer (49 papers) and Cancer, Hypoxia, and Metabolism (43 papers). Javier A. Menéndez is often cited by papers focused on Cancer, Lipids, and Metabolism (69 papers), Metabolism, Diabetes, and Cancer (49 papers) and Cancer, Hypoxia, and Metabolism (43 papers). Javier A. Menéndez collaborates with scholars based in Spain, United States and Australia. Javier A. Menéndez's co-authors include Ruth Lupu, Alejandro Vázquez‐Martín, Cristina Oliveras‐Ferraros, Begoña Martı́n-Castillo, Rámón Colomer, Jorge Joven, Luciano Vellón, Sílvia Cufí, Elisabet Cuyàs and Joaquim Bosch‐Barrera and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Clinical Oncology.
In The Last Decade
Javier A. Menéndez
309 papers receiving 16.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Javier A. Menéndez Spain | 71 | 10.1k | 6.3k | 3.8k | 1.6k | 1.6k | 314 | 16.6k | ||
| Zigang Dong United States | 88 | 17.1k 1.7× | 4.4k 0.7× | 5.7k 1.5× | 1.1k 0.7× | 1.4k 0.9× | 578 | 28.0k | ||
| Ann M. Bode United States | 77 | 12.4k 1.2× | 3.3k 0.5× | 4.1k 1.1× | 751 0.5× | 1.3k 0.8× | 422 | 21.1k | ||
| Chinthalapally V. Rao United States | 62 | 6.4k 0.6× | 4.2k 0.7× | 4.8k 1.3× | 1.5k 0.9× | 385 0.2× | 262 | 16.9k | ||
| Raymond N. DuBois United States | 91 | 10.8k 1.1× | 6.6k 1.0× | 7.1k 1.9× | 3.1k 1.9× | 1.1k 0.7× | 227 | 31.6k | ||
| Peter J. Houghton United States | 86 | 15.6k 1.5× | 3.2k 0.5× | 7.5k 2.0× | 1.1k 0.7× | 1.1k 0.7× | 571 | 28.8k | ||
| Hiroyasu Esumi Japan | 63 | 7.3k 0.7× | 3.8k 0.6× | 2.7k 0.7× | 1.5k 1.0× | 1.2k 0.8× | 288 | 14.4k | ||
| S. Perwez Hussain United States | 49 | 5.5k 0.5× | 3.0k 0.5× | 3.8k 1.0× | 941 0.6× | 952 0.6× | 100 | 11.5k | ||
| I. Bernard Weinstein United States | 79 | 13.6k 1.4× | 4.1k 0.7× | 5.9k 1.5× | 1.3k 0.8× | 631 0.4× | 377 | 21.9k | ||
| Kwang Seok Ahn South Korea | 77 | 10.5k 1.0× | 3.1k 0.5× | 3.7k 1.0× | 616 0.4× | 1.2k 0.8× | 361 | 19.0k | ||
| Garth Powis United States | 79 | 14.4k 1.4× | 3.9k 0.6× | 3.7k 1.0× | 897 0.6× | 798 0.5× | 388 | 22.2k |
Countries citing papers authored by Javier A. Menéndez
Since
Specialization
Citations
This map shows the geographic impact of Javier A. Menéndez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier A. Menéndez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier A. Menéndez more than expected).
Fields of papers citing papers by Javier A. Menéndez
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Javier A. Menéndez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier A. Menéndez. The network helps show where Javier A. Menéndez may publish in the future.
Co-authorship network of co-authors of Javier A. Menéndez
This figure shows the co-authorship network connecting the top 25 collaborators of Javier A. Menéndez. A scholar is included among the top collaborators of Javier A. Menéndez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier A. Menéndez. Javier A. Menéndez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Martı́n-Castillo, Begoña, et al.. (2025). Metabolic hallmarks of trastuzumab resistance. Expert Opinion on Therapeutic Targets. 29(7). 457–479.
2.
Cuyàs, Elisabet, Sara Verdura, George Kemble, et al.. (2025). Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer. Neoplasia. 62. 101143–101143.
3.
Menéndez, Javier A., Ruth Lupu, Begoña Martı́n-Castillo, et al.. (2025). Mitochondrial priming in therapy-induced senescence: implications for CAR-T/NK immunosenolytic therapy. Frontiers in Immunology. 16. 1695244–1695244.
4.
Vila, E., Sara Verdura, José Antonio Encinar, et al.. (2024). 1039P Discovery of a novel inhibitor of PD-L1 maturation that overcomes adaptive resistance to cancer immunotherapy. Annals of Oncology. 35. S697–S697.
5.
Verdura, Sara, José Antonio Encinar, Antonio Segura‐Carretero, et al.. (2022). Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors. Cancers. 14(24). 6101–6101.
6.
Verdura, Sara, Elisabet Cuyàs, Verónica Ruiz-Torres, et al.. (2021). Lung Cancer Management with Silibinin: A Historical and Translational Perspective. Pharmaceuticals. 14(6). 559–559.
7.
Tramonti, Angela, Elisabet Cuyàs, José Antonio Encinar, et al.. (2021). Metformin Is a Pyridoxal-5′-phosphate (PLP)-Competitive Inhibitor of SHMT2. Cancers. 13(16). 4009–4009.
8.
Papadimitropoulou, Adriana, Luciano Vellón, Ella Atlas, et al.. (2020). Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer. International Journal of Molecular Sciences. 21(20). 7737–7737.
9.
Menéndez, Javier A., et al.. (2017). The practice-changing QUARTZ trial: is there any role for whole brain radiotherapy in patients with non-small cell lung cancer and brain metastases?. Translational Cancer Research. 6(1).
10.
Rodríguez‐Gallego, Esther, María Guirro, Marta Riera-Borrull, et al.. (2014). Mapping of the circulating metabolome reveals α-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease. International Journal of Obesity. 39(2). 279–287.
11.
Cufí, Sílvia, Alejandro Vázquez‐Martín, Cristina Oliveras‐Ferraros, et al.. (2013). The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer. Scientific Reports. 3(1). 2469–2469.
12.
Menéndez, Javier A.. (2012). Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment. Oncology Reports. 27(6). 1887–92.
13.
Oliveras‐Ferraros, Cristina, Alejandro Vázquez‐Martín, Sílvia Cufí, et al.. (2011). Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies. Biochemical and Biophysical Research Communications. 407(2). 412–419.
14.
Menéndez, Javier A.. (2009). Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: Molecular mechanisms and therapeutic perspectives. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1801(3). 381–391.
15.
Vázquez‐Martín, Alejandro, et al.. (2009). The serine 2481-autophosphorylated form of mammalian Target Of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells. Biochemical and Biophysical Research Communications. 380(3). 638–643.
16.
Vázquez‐Martín, Alejandro, Rámón Colomer, Joan Brunet, & Javier A. Menéndez. (2007). Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.. PubMed. 31(4). 769–76.
17.
Domingo‐Echaburu, Saioa, et al.. (2007). Implantación de un programa de ajuste posológico en pacientes con función renal disminuida. 9(2). 102–106.
18.
Menéndez, Javier A., Alejandro Vázquez‐Martín, Santiago Ropero, et al.. (2006). HER2 (erbB-2)-targeted effects of the ϖ-3 polyunsaturated. Fatty acid α-linolenic acid (ALA; 18:3n-3) in breast cancer cells: the «fat features» of the «Mediterranean diet» as an «anti-HER2 cocktail». Clinical & Translational Oncology. 8(11). 812–820.
19.
Menéndez, Javier A., Luciano Vellón, & Ruth Lupu. (2005). Orlistat: From Antiobesity Drug to Anticancer Agent in Her-2/neu (erbB-2)-Overexpressing Gastrointestinal Tumors?. Experimental Biology and Medicine. 230(3). 151–154.
20.
Menéndez, Javier A., Santiago Ropero, Ruth Lupu, & Rámón Colomer. (2004). ω-6 polyunsaturated fatty acid γ-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. Oncology Reports. 11(6). 1241–52.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Zigang Dong Breakdown of academic impact, for papers by Ann M. Bode Breakdown of academic impact, for papers by Chinthalapally V. Rao Breakdown of academic impact, for papers by Raymond N. DuBois Breakdown of academic impact, for papers by Peter J. Houghton Breakdown of academic impact, for papers by Hiroyasu Esumi Breakdown of academic impact, for papers by S. Perwez Hussain Breakdown of academic impact, for papers by I. Bernard Weinstein Breakdown of academic impact, for papers by Kwang Seok Ahn Breakdown of academic impact, for papers by Garth Powis